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Introduction. Hypertension has been identified as one of the 
commonest modifiable determinants for chronic kidney disease 
progression. A variety of antihypertensive drugs are available and 
their effect on kidney function has been investigated by a large 
number of randomized controlled trials. Observational studies, 
although scarcely been used, outpatient can reflect everyday 
practice, where drug exposures vary over time, and may provide 
an alternative for detecting longitudinal changes in kidney function.
Materials and Methods. We applied mixed model repeated measures 
analysis to investigate the effect of antihypertensive drug categories 
and their combinations on kidney function change over time in a 
cohort of 779 patients with essential hypertension, using the data 
from a Greek hypertension outpatient clinic. Antihypertensive 
drugs were grouped in 5 categories. Their effect was evaluated 
and their combinations with and without renin-angiotensin-system 
inhibitors (RASI) to each other. In addition, the combination of 
RASI with calcium channel blockers (CCBs) was studied.
Results. Diuretics, RASI, CCBs, and beta-blockers had a significant 
renoprotective and blood pressure lowering effect. Combinations 
with RASI had a smaller beneficial effect on kidney function 
compared to CCBs (0.75 mL/min/1.73 m2 per year of drug use 
versus 0.97 mL/min/1.73 m2). There was no additional effect 
when combining RASI with CCBs. However, the lowering effect 
on systolic blood pressure was greater (-0.83 mm Hg per year of 
drug use, P < .001).
Conclusions. RASI were found to have a smaller, although 
significant, renoprotective effect. There was no additional effect 
on kidney function when combining RASI with CCBs.
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INTRODUCTION
Hypertension is a major cardiovascular risk factor 
and has been identified in randomized clinical trials 
and epidemiological studies as the 2nd commonest 
modifiable determinant for chronic kidney disease 
(CKD) progression, after diabetes mellitus.1-3 A 
large number of clinical studies have investigated 
the effect of antihypertensive treatment on kidney 
function.4 It is clear that optimal blood pressure 
control is the main objective of antihypertensive 
therapy; however, each antihypertensive drug class 
has unique characteristics and some drugs have 
been shown to have direct effects on intrarenal 
mechanisms, resulting in additional renal protection 
beyond lowering systemic blood pressure.5,6
Randomized controlled trials involve careful 
Kidney Function in Essential Hypertension—Ptinopoulou et al
193Iranian Journal of Kidney Diseases | Volume 11 | Number 3 | May 2017
se lec t ion  o f  par t i c ipants  that  may not  be 
representative of the general population. Individual 
effects of drug classes cannot be evaluated in 
this context. Observational studies using clinical 
databases can reflect everyday practice, where 
drug exposures vary over time and may provide 
an alternative to clinical trial data for detecting 
longitudinal changes in blood pressure. The 
analysis of such data can present a methodological 
challenge because of missing data, heterogeneity 
of follow-up intervals, and great variability in 
drug use within and between patients.7 This study 
aimed to investigate the effect of antihypertensive 
drug categories and their combinations on kidney 
function change over time in patients with 
essential hypertension, using the data from a Greek 
hypertension outpatient clinic.
MATERIALS AND METHODS
Study Design
We conducted a retrospective cohort study using 
the database of an outpatient hypertension clinic, in 
order to investigate the effect of antihypertensive 
treatment on kidney function and blood pressure 
control in patients with essential hypertension in 
the complex real world settings, accounting for the 
variability of the data of everyday clinical practice.
Population
Data was extracted from the computerized 
medical records of hypertension outpatient clinics 
of the 1st Department of Internal Medicine of 
AHEPA University Hospital in Thessaloniki, 
Greece. Participants were adults with essential 
hypertension, followed up for at least 3 years 
between January 1990 and July 2011 that were 
not on end-stage renal disease. Patients with 
diabetes mellitus at baseline, as well as patients 
with secondary forms of hypertension, primary 
kidney disease, chronic use of nonsteroidal anti-
inflammatory drugs or corticosteroids, cancer, 
active liver disease, pregnancy, and alcohol or 
drug abuse were excluded from the study. The 
patients were followed up until last study visit 
or loss to follow up.
Patients were divided into 3 subgroups according 
to the frequency of follow-up, in order to investigate 
whether shorter intervals between visits at the 
outpatient clinic are associated with better blood 
pressure control and better kidney function 
preservation. The first group included those with 
a mean visit rate less than 1 year, the second group 
consisted of people who had a mean visit frequency 
between 1 and 2 years, and the last one included 
patients coming less often (mean visit rate more than 
2 years). Moreover, patients were divided within the 
interval groups based on the mean systolic blood 
pressure (SBP) during the follow-up (less than 140 
mmHg, between 140 mm Hg and 159 mmHg, and 
equal or greater than 160 mm Hg).
Measurements and Assessments of Predictors
A validated mercury sphygmomanometer was 
used, with appropriate cuff size, to obtain at least 
2 blood pressure measurements. Kidney function 
was assessed by estimated glomerular filtration 
rate (GFR), which was calculated by the simplified 
the Modification of Diet in Renal Disease study 
equation.8 Diabetes mellitus was identified based 
on a physician diagnosis, use of antidiabetic drugs, 
or a fasting serum glucose greater than 125 mg/
dL at baseline.
Antihypertensive Drug Exposure
A variety of substances were used throughout 
the cohort. These were classified into the following 
categories:  angiotensin-converting enzyme 
inhibitors (ACEIs), angiotensin receptor antagonists 
(ARBs), beta-blockers, calcium channel blockers 
(CCBs), dihydropyridines (dihydropyridines), 
and nondihydropyridines, diuretics (thiazides, 
chlorthalidone, furosemide, and amiloride), 
and other drugs, which included central acting 
agents and alpha-blockers. Exposure to treatment 
was assessed by the  number  of  days  each 
pharmacological entity was used.9
Moreover,  we identified combinations of 
antihypertensive categories and compared their 
blood pressure lowering effect and renoprotective 
effect. We compared combinations with or without 
a renin-angiotensin system inhibitor (RASI). We 
compared also the following combinations: (a) 
including a RASI but no CCB, (b) including a CCB 
but not a RASI, (c) combinations of RASI with 
CCBs, and (d) other combinations.
Statistical Analysis
For the analysis of the continuous effect of 
antihypertensive treatment on blood pressure and 
kidney function (GFR), we used repeated measures 
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analysis in a mixed effects model. Random intercept 
and random slope were included in the model to 
encounter effectively the variability of different 
baseline and different trajectories between subjects 
and within subjects. Unstructured covariance 
structure was used, which allows for the variance 
and the correlation between any two measurements 
to be different at all time points, ie, obtaining 
unique estimates for the variance of subject-specific 
intercepts, slopes, and covariances.10,11 The mean 
differences of GFR, SBP, diastolic blood pressure 
(DBP), and mean arterial pressure (MAP) between 
the interval subgroups, as well as between SBP 
groups for GFR, were evaluated in a similar model.
Descriptive statistics were used to evaluate 
baseline characteristics of the population, as 
well as summarize antihypertensive drug use. 
All analyses were performed using the the SPSS 
software (Statistical Package for the Social Sciences, 
version 20.0, SPSS Inc, Chicago, IL, USA). All P 
values were considered significant at .05 level.
RESULTS
Population Selection and Characteristics
From a total number of 6310 patients, 1923 
had no follow-up monitoring of kidney function 
or incomplete entries of medication, 1576 had 
attended the clinic only once, and 764 had less than 
3 years of follow-up. From the rest, 2047 patients; 
853 were diabetic patients; 11 patients developed 
acute kidney injury, obstructive uropathy, or end-
stage renal disease during follow-up; 15 patients 
were not on any antihypertensive medication; 
and 389 patients had either secondary forms of 
hypertension or chronic use of nonsteroidal anti-
inflammatory drugs or steroids, history of cancer, 
active liver disease, pregnancy or alcohol abuse 
(Figure). Finally, 779 patients were included with a 
median follow-up of 7.02 years (interquartile range, 
4.51 to 10.31). Of these patients, 148 (20.2%) had a 
GFR equal or greater to 90 mL/min, 481 (65.7%) 
had a GFR between 60 mL/min and 89 mL/min, 
90 (12.3%) had a GFR between 45 mL/min and 
59 mL/min, and 3 (1.8%) had a GFR between 30 
mL/min and 44 mL/min. Table 1 describes the 
Frequency of Visit
Characteristics All Patients < 1 Year 1 to 2 Years > 2 Years
Number of patients 779 405 228 146
Age, y 57.7 ± 9.8 58.1 ± 10.5 57.6 ± 9.1 60.2 ± 9.0
Sex
Male 240 (30) 127 (31) 63 (28) 50 (34)
Female 539 (70) 278 (69) 165 (72) 96 (66)
Systolic blood pressure, mm Hg 150 ± 15 149 ± 16 151 ± 14 149 ± 16
Diastolic blood pressure, mm Hg 90 ± 9 90 ± 9 90 ± 8 87 ± 8
Mean arterial pressure, mm Hg 110 ± 9 110 ± 9 111 ± 8 108 ± 9
Body mass index, kg/m2 30.3 ± 4.4 30.2 ± 4.3 30.5 ± 4.7 30.5 ± 4.8
Glomerular filtration rate, mL/min 75.8 ± 16.6 75.1 ± 16.9 75.5 ± 15.3 75.6 ± 21.7
Smoker 140 (18) 81 (20) 40 (17) 19 (13)
Median follow-up (interquartile range), y 7.02 (4.51, 10.31) 5.53 (3.95, 8.57) 7.63 (5.29, 10.79) 8.84 (6.44, 12.29)
Table 1. Baseline Characteristics and Follow-up*
*Values are mean ± standard deviation for continuous variables and frequency (percent) for categorical variables, unless otherwise specified.
Flowchart of study population.
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baseline characteristics of the study population.
Follow-up Intervals
The median return visit interval was 83 days 
(interquartile range, 27 to 265). Assessing the 
patients defined by follow-up interval groups, there 
were no significant differences at baseline between 
group means for age (F(12,762) = 1.180, P = .31), 
SBP (F(2,761) = 0.949, P = .39), DBP (F(2,755) = 0.431, 
P = .65), MAP (F(2,755) = 0.938, P = .39), and GFR 
(F(2,716) = 1.805, P = .17), as determined by the 
1-way analysis of variance. The sex distribution 
was similar across the three groups (x2(2) = 1.29, 
P = .52). Follow-up time was significantly longer 
in lower-visit frequency groups, as it was shown 
in the Kruskal-Wallis test analysis (P < .001).
In mixed models adjusted for age and sex, lower 
frequency of visit was associated with higher mean 
SBP, DBP, and MAP over time; however, this was 
not found to be significantly associated with GFR 
change (Table 2). In a separate analysis including 
SBP groups along with interval groups, frequency 
of follow-up was not found to have a significant 
effect on kidney function change as above; however, 
the worse SBP control had a significant negative 
impact on GFR (β estimate = -7.5 and P = .003 for 
SBP greater than 160 mm Hg and β estimate = -3.0 
and P = .045 for SBP of 140 mm Hg to 159 mm Hg, 
compared to patients with mean SBP during follow-
up less than 140 mm Hg). It is notable that the less 
frequent the attendance to the hypertension clinic 
was, the higher the percentage of uncontrolled SBP 
was, as it is depicted in Table 3.
Medication Use
Table 4 shows the persistence of drug use, 
depicted as the average total years of drug use. 
Persistence rates were assessed as the number of 
patients still using the drug category at the last visit 
divided by the total number of patients that had 
been prescribed the medication. The results reveal 
that RASI had the greater persistence rate (84.3%), 
although similar to CCBs (83.5%), followed by 
diuretics (77.4%). Angiotensin-converting enzyme 
inhibitors had a lower persistence rate than ARBs 
(44.7% versus 86.8%), and nondihydropyridine 
had a lower persistence rate than dihydropyridine 
(52.1% versus 74.7%). The characteristics of patients 
using the studied drug combinations during the 
course of treatment are shown in Table 5 and they 
were similar among the different groups.
Effect of Antihypertensives on Kidney Function 
and Blood Pressure Control
In univariable analyses, adjusting for SBP, all 
drug categories, apart from “other drugs,” were 
found to have significant renoprotective effects 
(positive estimates), where β estimates represent 
the change of GFR in mL/min/1.73m2 by each year 
Visits Every 1 to 2 Years Visits Longer Than Every 2 years
Parameter Βeta Estimate ± Standard Error P Βeta Estimate ± Standard Error P
Systolic blood pressure 4.20 ± 0.86 < .001 4.73 ± 1.09 < .001
Diastolic blood pressure 1.42 ± 0.39 < .001 1.69 ± 0.49 .001
Mean arterial pressure 2.37 ± 0.47 < .001 2.71 ± 0.60 < .001
Glomerular filtration rate -0.24 ± 1.18 .08 0.28 ± 1.46 .85
Table 2. Changes Over the Follow-up Period by Interval Visits Groups*
*Reference group is patients with visit rate less than a year. Analysis is adjusted for age and sex.
Systolic Blood Pressure 
Category, %
Visit Interval
< 1 Year 1 to 2 Years > 2 Years
< 140 mm Hg 40.0 24.1 25.0
140 mm Hg to 159 mm Hg 49.6 62.3 53.8
≥ 160 mm Hg 10.4 13.6 21.2
Table 3. Percentage of Patients in Each Mean Systolic Blood 
Pressure Category Over the Follow-up Period by Interval Visits 
Groups
Medication Category Mean Use, y* Persistence Rate, %
Renin-angiotensin-system 
inhibitors
5.19 ± 4.12 84.3
Angiotensin-converting enzyme 
inhibitors 
4.63 ± 4.19 44.7
Angiotensin receptor blockers 3.01 ± 2.81 86.8
Calcium channel blockers 5.18 ± 4.04 83.5
Dihydropyridines 4.52 ± 3.81 74.7
Nondihydropyridines 3.45 ± 3.63 52.1
Diuretics 5.13 ± 4.14 77.4
Beta-blockers 5.28 ± 4.52 63.8
Table 4. Persistence in Medication Use
*Values are mean ± standard deviation.
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of drug use. The CCBs, diuretics, and beta-blockers 
had similar β estimates; however, RASI had a 
smaller renoprotective effects. The beneficial effect 
of antihypertensive drugs was beyond the effect 
of blood pressure, since SBP was included in the 
model as a covariate. Moreover, all drug categories, 
apart from “other drugs,” had significant and 
similar negative β estimates for SBP (representing 
the change in mm Hg by each year of drug use), 
with a slightly greater lowering effect for RASI 
(Table 6).
Drug combinations including RASI were 
compared to drug combinations without RASI in 
mixed models analysis. Both groups were found to 
have significant renoprotective and blood pressure 
lowering effects by each year of drug use. Including 
a RASI in the treatment regime was found to have 
a greater lowering effect on SBP; however, the β 
estimate for GFR was smaller. When comparing 
combinations including either a RASI or a CCB, 
both groups had significant positive estimates for 
GFR, with a higher β estimate for combinations of 
CCB, and similar significant negative estimates for 
SBP. The combination of RASI with CCB had a 
greater lowering effect on SBP than using either of 
these categories separately. However, no additional 
renoprotective effect was found (P = .26). When 
neither a RASI nor a CCB were used, the effect on 
kidney function was not found to be significant 
(Table 7).
All analyses were adjusted for age, sex, body 
mass index, and smoking status. Age had a 
significant negative effect on GFR, which is 
biologically plausible and is consistent with the 
aging kidney. Body mass index and smoking status 
were not found to have any significant effects on 
GFR; however, body mass index was significantly 
associated with higher SBP.
DISCUSSION
The present study showed that through the 
variety of follow-up and drug use, outpatient 
clinic data can effectively be used for evaluating 
the impact of antihypertensive medication on 
blood pressure control and kidney function. 
Closer follow-up was associated with better 
blood pressure control, probably providing more 
opportunities for intensification of medication as 
well as enhancing treatment adherence.12,13 All 
categories of antihypertensive drugs were found to 
Drug Combinations Including RASI
Without 
RASI
CCB Plus 
RASI
RASI Without 
CCB
CCB Without 
RASI
Other 
Combinations
Number of patients 577 322 423 340 267 117
Sex
Male 169 (29) 77 (24) 127 (30) 93 (27) 63 (24) 21 (18)
Female 408 (71) 77 (76) 127 (70) 93 (73) 63 (76) 21 (82)
Age, y 65.0 ± 8.9 61.9 ± 10.2 66.6 ± 8.3 62.1 ± 9.3 62.4 ± 10.7 60.5 ± 8.4
Systolic blood pressure, mm Hg 145 ± 16 145 ± 16 147 ± 16 143 ± 16 144 ± 16 147 ± 15
Diastolic blood pressure, mm Hg 85 ± 8 85 ± 8 85 ± 8 86 ± 7 85 ± 8 87 ± 8
Body mass index, kg/m2 30.6 ± 4.6 31.1 ± 4.8 30.5 ± 4.7 30.7 ± 4.4 30.9 ± 4.9 31.6 ± 4.6
Glomerular filtration rate, mL/min 75.8 ± 21.0 75.8 ± 21.0 75.8 ± 21.0 78.6 ± 19.9 75.9 ± 20.7 78.7 ± 20.8
Smokers 115 (80) 45 (86) 87 (79) 64 (81) 40 (85) 11 (91)
Duration of use 4.53 ± 3.90 4.14 ± 3.67 3.46 ± 3.34 3.39 ± 3.31 3.38 ± 3.30 3.67 ± 3.46
Table 5. Characteristics of Patients With Different Treatment Combinations*
*Values are mean ± standard deviation or frequency (percentage). RASI indicates renin-angiotensin-system inhibitor and CCB, calcium channel 
blocker.
Estimated Glomerular Filtration Rate Systolic Blood Pressure
Covariate Βeta Estimate ± Standard Error P Βeta Estimate ± Standard Error P
Renin-angiotensin-system inhibitors 0.50 ± 0.13 < .001 -0.55 ± 0.09 < .001
Calcium channel blockers 0.67 ± 0.14 < .001 -0.52 ± 0.09 < .001
Diuretics 0.60 ± 0.14 < .001 -0.47 ± 0.09 < .001
Beta-blockers 0.66 ± 0.16 < .001 -0.40 ± 0.10 < .001
Other medications 0.84 ± 0.58  .15 1.42 ± 0.37 < .001
Table 6. Univariable Analysis of the Effect of Antihypertensive Drug Categories*
*Beta estimates represent changes in kidney function in mL/min/1.73m2 and changes in systolic blood pressure in mm Hg. For medications, the 
change is per year of medication use.
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have a similar significant renoprotective and blood 
pressure lowering effect in univariable analyses, 
adjusting for SBP (in the GFR model), age, sex, body 
mass index and smoking status. When combinations 
of drug categories were evaluated, it was found 
that combinations including RASI had a better 
effect on blood pressure control than combinations 
without a RASI, while the effect on kidney function 
for both groups was protective, although slightly 
smaller for the RASI group. Moreover, the results 
showed that there was no additional effect on 
kidney function when combining RASI with CCBs, 
although the lowering effect on SBP was greater.
Unlike clinical trials, where the drug effects are 
evaluated in an ideal study setting, the effectiveness 
and clinical impact of drug use can be confirmed 
in the target population in real life settings, when 
outpatient clinic databases are used. These usually 
include patients with variable intervals of visits, 
different follow-up periods, and variable number 
of observations.14 Moreover, a variety of drugs are 
used within and between patients for a variable 
time period. We used mixed model repeated 
measures analysis, which is the most effective 
analysis for such databases. Mixed models can 
overcome limitations of other methods and help 
understand better the true nature of change, by 
giving information about individual or group 
growth trajectories.8,11
Real life data are not usually available on large 
sets of patients. The most widely used clinical 
database in Europe for pharmacoepidemiological 
studies is the General Practice Research Database 
in the United Kingdom (known as the Clinical 
Practice Research Datalink since March 2012), 
with millions of patients. Examples of the General 
Practice Research Database cohort studies related 
to blood pressure control and drug treatment are 
one by Delaney and associates, who validated 
the effect of non-antihypertensive drug treatment 
on blood pressure,7 including nonsteroidal anti-
inflammatory drugs, statins, warfarin, and proton 
pump inhibitors, as well as another study by 
Burke and coworkers, who evaluated the effect 
of antihypertensive drugs on new-onset diabetes 
mellitus.15
Searching the PubMed (through March 2016), we 
found only 2 recent retrospective cohort studies 
that investigated the impact of RASI on CKD 
progression, using the data from the Veterans 
Affairs System in the United States. Arora and 
colleagues, in their recent study (December 2015), 
showed that the use of RASI was not associated 
with less hazard of CKD progression or mortality 
in elderly patients without diabetes mellitus or 
proteinuria compared to other antihypertensive 
Estimated Glomerular Filtration Rate Systolic Blood Pressure
Covariate Βeta Estimate ± Standard Error P Βeta Estimate ± Standard Error P
Combinations Including RASI or Not
RASI combinations 0.47 ± 0.15 .002 -0.62 ± 0.10 < .001
No RASI combinations 0.79 ± 0.21 < .001 -0.45 ± 0.13 .001
Age -0.53 ± 0.05 < .001 0.37 ± 0.04 < .001
Female sex -8.33 ± 1.14 < .001 4.78 ± 0.87 < .001
Smoking 2.25 ± 1.34 .09 -0.91 ± 1.02 .37
Body mass index 0.09 ± 0.11 .38 0.57 ± 0.08 < .001
Systolic blood pressure -0.05 ± 0.02 .03 … …
Combinations of RASI and CCBs
RASI without CCB 0.75 ± 0.22 .001 -0.34 ± 0.15 .02
CCB without RASI 0.97 ± 0.26 < .001 -0.48 ± 0.16 .003
RASI and CCB 0.23 ± 0.20 .26 -0.83 ± 0.13 < .001
Other Combinations 0.49 ± 0.34 .15 -0.38 ± 0.22 .08
Age -0.53 ± 0.05 < .001 0.38 ± 0.04 <.001
Female sex -8.29 ± 1.14 < .001 4.79 ± 0.87 < .001
Smoking 2.23 ± 1.34 .10 -1.02 ± 1.02 .32
Body mass index 0.09 ± 0.11 .38 0.57 ± 0.08 < .001
Systolic blood pressure -0.05 ± 0.02 .03 … ...
Table 7. Multivariable Analysis of Combinations of Antihypertensive Drug Categories*
*Beta estimates represent changes in kidney function in mL/min/1.73m2 and changes in systolic blood pressure in mm Hg. For medications, the 
change is per year of medication use. RASI indicates renin-angiotensin-system inhibitor and CCBs, calcium channel blockers.
Kidney Function in Essential Hypertension—Ptinopoulou et al
198 Iranian Journal of Kidney Diseases | Volume 11 | Number 3 | May 2017
medications.16 This is relevant to our finding of 
slightly lower magnitude of renoprotective benefit 
in the group of RASI. On the other hand, Molnar 
and coworkers found that patients treated with 
RASI had lower odds of mortality than patients not 
treated with RASI. However, in this study, patients 
receiving an ACEI or ARB were more likely to be 
diabetic with proteinuria, and stratified analysis 
showed that the effect of RASI on mortality was 
not significant in nondiabetic patients.17
Our study included nondiabetic patients with 
an average younger age, while the majority of 
them had normal or only mildly impaired kidney 
function. The study period was longer in total 
and evaluated the impact of all antihypertensive 
drug categories and their combinations on the 
rate of kidney function change over time, rather 
than specific cutpoint outcomes. To the best of our 
knowledge, there is no other study analyzing the 
change of kidney function over time in real life 
settings, in terms of antihypertensive medication 
treatment.
Our results showed a slightly lower magnitude 
of renoprotective benefit in the group of RASI. 
Having been widely studied, ACEIs and ARBs 
have been shown to protect the glomeruli by 
reducing intraglomerulus blood pressure and 
proteinuria.5,6 However, in our study, patients 
with diabetes mellitus or glomerulonephritis were 
not included, and although proteinuria was not 
regularly monitored, it is unlikely to have been a 
major factor. Moreover, in our cohort, patients with 
impaired kidney function were presumably more 
likely to have a degree of renovascular disease, as 
patients with other primary and secondary causes 
of kidney disease were excluded from the study. 
In such a group of patients, the beneficial effect of 
RASI may not be the same as in individuals with 
proteinuria, diabetes mellitus, and CKD. Certainly, 
it would have been interesting to see the effects 
of RASI in comparison between diabetics and 
nondiabetics, if diabetic patients were included 
in the study.
In addition, calcium antagonists have been 
shown to be effective for reducing blood pressure, 
through their vasodilating effect on afferent 
arteriole of the glomerulus, although this can 
result in increased transmission of pressure into 
the glomerulus, when systematic blood pressure 
is not well controlled. In our study, CCBs were 
found to have a beneficial effect both in univariable 
and multivariable analyses.
As far as the combination of RASI with CCBs 
is concerned, Bakris and colleagues showed that 
combining an ACEI with a nondihydropyridine 
CCB can reduce proteinuria to a greater extent than 
either agent alone in patients with type 2 diabetes 
mellitus.18 Moreover, the Irbesartan Diabetic 
Nephropathy Trial and the African American Study 
of Kidney Disease and Hypertension showed that 
dihydropyridines failed to reduce proteinuria and 
to slow the progression of nephropathy in the 
absence of agents that block the RASI.6,19 However, 
these studies included patients with advanced 
nephropathy and proteinuria. A post-hoc analysis 
of another similar study for renal outcomes did 
not show any significant differences between 
amlodipine, Lisinopril, and chlorthalidone in 
hypertensive patients with reduced GFR.20 A recent 
meta-analysis of Huang and coworkers examined 
the effect of the combination of RASI and CCB 
on kidney function, including 628 hypertensive 
patients with CKD from 7 randomized controlled 
trials.21 The results showed that the combination of 
RASI with a CCB had a greater lowering effect on 
SBP compared to RASI monotherapy. However, it 
did not show any additional renoprotective effect 
for the combination treatment. These conclusions 
were consistent with the findings of our study.
Our findings are limited by the fact that we do 
not know the causes of patients’ loss to follow-up 
and we can only assume deliberately not attending 
to the clinic, death, or end of the study. In patients 
for whom the interval between visits was quite 
extended, we tried to cover as best as possible 
potential factors affecting kidney function from 
the history of the patient as it was recorded in the 
database. However, the results of the study may be 
biased by morbidity and mortality, since we did 
not censor that. Moreover, information regarding 
compliance to medication were not available, and 
the reasons of changing drug categories during 
the course of treatment (crossovers) were not 
systematically documented and could include 
ineffective blood pressure control or a drug 
adverse effect.
Finally, proteinuria, a surrogate marker of kidney 
disease, was not routinely monitored, although, as 
previously mentioned, we could assume that this 
was not a significant factor. More accurate and 
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valuable results can be obtained with increased 
numbers of patients and years of follow-up, so 
larger outpatient database studies can evaluate 
further the antihypertensive drugs’ effect on kidney 
function in the complicated settings of everyday 
clinical practice.
CONCLUSIONS
The results of the present study implied that 
outpatient records can be a useful tool in estimating 
blood pressure control and kidney function change 
over time, secondary to drug therapy, when 
appropriate statistical techniques are used. The 
importance of regular follow-up visits has been 
depicted in previous studies and is confirmed 
in the present study, which included patients 
with variable and longer follow-up intervals. 
All 5 antihypertensive drug categories had a 
significant renoprotective effect that was beyond 
blood pressure control in univariable analysis, 
although RASI were found to have a slightly smaller 
beneficial effect on kidney function in a nondiabetic 
population with essential hypertension. Moreover, 
there was no additional effect when combining 
RASI with CCBs, although this combination, as 
well as combinations including RASI, were found 
to have a better blood pressure lowering effect.
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